2024-09-08 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and sells a wide range of healthcare products, including pharmaceuticals, medical devices, diagnostics, and nutrition products. 

**Performance Analysis:**

1. **Relative Performance:**
    - ABT's cumulative return of 42.44% lags behind the S&P 500's (VOO) return of 81.34%.
    - The relative performance gap stands at -38.9%, which falls within the historical range of -53.92% to 25.37%.
    -  The relative performance is currently at the 24.27th percentile, indicating it has performed better than 24.27% of historical periods.

2. **Recent Price Movements:**
    - Closing price: $113.86
    - 5-day moving average: $113.86
    - 20-day moving average: $111.81
    - 60-day moving average: $107.22
    - The stock price is currently above all three moving averages, suggesting a bullish trend.

3. **Technical Indicators:**
    - RSI: 66.03, indicating the stock is in overbought territory, suggesting potential for a pullback.
    - PPO: -0.05, implying a slightly bearish sentiment.
    - Delta_Previous_Relative_Divergence: 2.27, indicating a slight positive divergence, suggesting a potential bullish reversal. 
    - Expected_Return: 24.1%, representing the potential maximum 5-year expected return on invested capital.

4. **Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

- The latest earnings report shows an EPS of $0.74 with revenue of $10.38 billion. 
- While the most recent earnings beat expectations, the overall trend suggests a gradual growth in EPS and revenue.
- The company has maintained consistent performance, demonstrating its ability to navigate the market effectively.

**Overall Analysis:**

ABT exhibits a mixed performance picture. While the stock is currently above its moving averages, suggesting a positive trend, it lags behind the market and is showing signs of overbought territory. The recent earnings report indicates continued growth but remains below historical peaks. The long-term expected return of 24.1% suggests potential for growth, although investors should exercise caution given the current high valuation and potential for a pullback. 

**Further Research:**

- Analyze the impact of various segments (pharmaceuticals, medical devices, diagnostics, and nutrition) on overall performance.
- Evaluate the company's competitive landscape and market share in each segment.
- Explore potential risks, such as regulatory changes and competition.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research before making any investment decisions.